PAHC · NASDAQ
Phibro Animal Health Corporation
$39.32 +1.66 (+4.41%)
Company overview
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NASDAQ
- Market cap
- $1.6B
- Employees
- 1,940
- Headquarters
- Teaneck, NJ
- Website
- pahc.com
- CEO
- Jack Clifford Bendheim
- Listed
- April 11, 2014
- P/E
- 16.80
- Dividend yield
- 1.20%
Company financials
- Revenue
- $1.5B
- Gross profit
- $487M
- Operating income
- $184M
- EBITDA
- $235M
- Net income
- $95.2M
- EPS
- $2.34
- Total assets
- $1.4B
- Total debt
- $787M
- Gross margin
- 32.49%
- Net margin
- 6.35%
- Earnings yield
- 5.95%
Showing FY 2026
PAHC
1D
NASDAQ
O38.93H39.53L37.35C37.65-1.09 (-2.81%)Vol289.49K
News